Trial Profile
Eculizumab to Enable Renal Transplantation in Patients With History of Antiphospholipid Antibody Syndrome or Catastrophic Antiphospholipid Antibody Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Oct 2020
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Antiphospholipid syndrome; Renal failure
- Focus Therapeutic Use
- 01 Oct 2020 Status changed from active, no longer recruiting to completed.
- 30 Mar 2017 Planned End Date changed from 1 Aug 2016 to 1 Jul 2020.
- 30 Mar 2017 Planned primary completion date changed from 1 Aug 2016 to 1 Jul 2020.